BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
Press Release|Articles|July 31, 2025
Camber Pharmaceuticals Adds Metformin Hydrochloride Oral Solution to Growing Portfolio
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals has launched Metformin Hydrochloride Oral Solution to improve glycemic control in type 2 diabetes patients aged 10 and older.
- The solution is intended as an adjunct to diet and exercise, providing a liquid alternative to traditional metformin tablets.
Advertisement
Camber Pharmaceuticals, a leader in generic drug approvals and launches, is proud to add Metformin Hydrochloride Oral Solution [met-FOR-min] to its growing portfolio
Metformin Hydrochloride Oral Solution is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Metformin Hydrochloride Oral Solution is available in 500 mg/5 mL, 16 oz. bottle.
To learn more about Metformin Hydrochloride Oral Solution, please visit:
Advertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement